EP Wealth Advisors LLC Lowers Stock Holdings in Haleon plc (NYSE:HLN)

EP Wealth Advisors LLC lowered its stake in shares of Haleon plc (NYSE:HLN) by 13.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,326 shares of the company’s stock after selling 3,656 shares during the quarter. EP Wealth Advisors LLC’s holdings in Haleon were worth $223,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Procyon Advisors LLC grew its holdings in shares of Haleon by 41.3% during the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after buying an additional 67,329 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Haleon by 29.8% during the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after buying an additional 475,934 shares during the last quarter. SeaCrest Wealth Management LLC purchased a new stake in Haleon in the 4th quarter valued at approximately $102,000. Atria Wealth Solutions Inc. boosted its holdings in Haleon by 6.1% in the 4th quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company’s stock valued at $457,000 after purchasing an additional 2,758 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in Haleon by 13.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company’s stock valued at $8,114,000 after purchasing an additional 99,666 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

HLN stock opened at $10.46 on Wednesday. The firm has a 50 day moving average of $10.21 and a 200-day moving average of $9.85. Haleon plc has a 12-month low of $8.25 and a 12-month high of $10.85. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $47.18 billion, a price-to-earnings ratio of 30.76, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. As a group, equities analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Barclays reaffirmed an “overweight” rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective on the stock in a report on Friday, May 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a report on Monday, March 3rd. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.